BSX Q3 Results Reset Growth Expectations as 2027 Outlook Stays Weak

Boston Scientific’s Q3 2026 organic sales grew 1.5% to $5.14 billion, below prior 3%-5% guidance, after an eight-business-day cybersecurity disruption reduced growth by about 300 bps. Adjusted EPS fell 3% to $0.73, below $0.80-$0.82 guidance; the company cut its 2026 organic growth outlook to approximately 3.75% from 5%-6% and EPS guidance to $3.16-$3.18 from $3.28-$3.32. Management expects 2027 to be the cycle trough, with improvement in 2028; the article also cites ongoing electrophysiology and WATCHMAN weakness and a Zacks Rank of #5 (Strong Sell).

Analysis

The key distinction is between a temporary execution shock and a franchise problem: production normalization could restore some lost volume and absorption, but it does not repair electrophysiology share losses or WATCHMAN softness. That mix makes a quick earnings rebound less likely than the cyber-related EPS impact alone suggests, and shifts valuation support toward a 2028 launch cycle—leaving BSX exposed to further estimate cuts before the payoff arrives.

ABT is the clearest relative beneficiary: its EP momentum can compound through physician experience, account adoption and competitor displacement, potentially raising the cost of BSX winning back share even after FARAWAVE Ultra launches. JNJ adds competitive pressure, though the evidence cited is less direct. PEN may add growth to BSX after closing, but acquisition contribution should not be treated as proof of organic recovery; integration and deal economics need verification.

Near term (days to weeks), expect estimate and positioning pressure to matter more than the one-off cyber charge. Over 1–3 months, watch quarterly shipment normalization, EP growth/share indicators, WATCHMAN trends and guidance revisions. Over 6–18 months, the risk is that competitive gains become durable before BSX’s product response; the bull case requires the rest of the portfolio to fund the trough without further deterioration. Contrarian point: the disruption may be recoverable, but treating the full shortfall as transient underweights the independently visible franchise weakness. Falsify the cautious view if BSX stabilizes EP and WATCHMAN before the 2028 launch window and restores margins as production normalizes.

Key Decisions for Investors

• Prefer a modest ABT-over-BSX pair rather than an outright sector short: it expresses relative EP execution while limiting broad medtech exposure. Reassess if ABT’s EP growth decelerates or BSX reports stabilization in share and franchise sales.
• Avoid adding to BSX ahead of evidence that shipments and manufacturing absorption normalize; the next results and any guidance update are nearer-term catalysts than the distant launch-led recovery.
• Track BSX EP and WATCHMAN sales/share, gross-margin recovery, and customer inventory normalization. If these improve while guidance holds, reduce the relative short; if share erosion persists or estimates are cut again, the trough may be deeper or longer than management indicates.
• Treat PEN as an event/watch item, not a standalone growth offset: verify closing timing, financing and the acquired business’s contribution before crediting the deal with improving BSX’s organic trajectory.